[go: up one dir, main page]

WO2005024755A3 - Medicaments for the treatment of neurodegenerative disorders or diabetes - Google Patents

Medicaments for the treatment of neurodegenerative disorders or diabetes Download PDF

Info

Publication number
WO2005024755A3
WO2005024755A3 PCT/US2004/011922 US2004011922W WO2005024755A3 WO 2005024755 A3 WO2005024755 A3 WO 2005024755A3 US 2004011922 W US2004011922 W US 2004011922W WO 2005024755 A3 WO2005024755 A3 WO 2005024755A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
kinase
treatment
compounds
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/011922
Other languages
French (fr)
Other versions
WO2005024755A2 (en
Inventor
Daniel L Flynn
Peter A Petillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/746,607 external-priority patent/US7279576B2/en
Priority claimed from US10/746,460 external-priority patent/US7144911B2/en
Priority claimed from US10/746,545 external-priority patent/US20040171075A1/en
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of WO2005024755A2 publication Critical patent/WO2005024755A2/en
Publication of WO2005024755A3 publication Critical patent/WO2005024755A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel compounds and methods are provided for the treatment of human neurodegenerative diseases, diabetes, mental conditions, inflammatory diseases, strokes and cancers. The compounds are small molecule inhibitors of glycogen synthease kinase-3 proteins. GSK-3 kinase protein/small molecule inhibitor compound adducts are also described wherein the compounds are bonded to the kinase proteins at the region of a protein switch control pocket in order to alter the conformation and/or protein activity of the kinases.
PCT/US2004/011922 2002-12-31 2004-04-15 Medicaments for the treatment of neurodegenerative disorders or diabetes Ceased WO2005024755A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US43730402P 2002-12-31 2002-12-31
US46380403P 2003-04-18 2003-04-18
US60/463,804 2003-04-18
US10/746,607 US7279576B2 (en) 2002-12-31 2003-12-24 Anti-cancer medicaments
US10/746,460 2003-12-24
US10/746,460 US7144911B2 (en) 2002-12-31 2003-12-24 Anti-inflammatory medicaments
US10/746,607 2003-12-24
US10/746,545 2003-12-24
US10/746,545 US20040171075A1 (en) 2002-12-31 2003-12-24 Modulation of protein functionalities
US10/437,304 2003-12-31

Publications (2)

Publication Number Publication Date
WO2005024755A2 WO2005024755A2 (en) 2005-03-17
WO2005024755A3 true WO2005024755A3 (en) 2005-04-21

Family

ID=34317765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011922 Ceased WO2005024755A2 (en) 2002-12-31 2004-04-15 Medicaments for the treatment of neurodegenerative disorders or diabetes

Country Status (1)

Country Link
WO (1) WO2005024755A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
ES2732230T3 (en) 2007-04-11 2019-12-12 Canbas Co Ltd Compounds that nullify the G2 control point of the cell cycle for use in cancer treatment
SI2712358T1 (en) 2011-05-13 2017-03-31 Array Biopharma, Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RU2664541C2 (en) 2012-11-13 2018-08-20 Эррэй Биофарма Инк. Bicyclic urea, thiourea, guanidine and cyanohuanidine compounds, useful for the treatment of pain
ES2664331T3 (en) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compounds of N-pyrrolidinyl, N'-pyrazolylurea, thiourea, guanidine and cyanoguanidine as Trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
PT3154959T (en) 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
JP2021512105A (en) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー Combination therapy for the treatment of gastrointestinal stromal tumors
JP7523351B2 (en) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー Combination Therapy for the Treatment of Mastocytosis - Patent application
TWI878335B (en) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US20230125667A1 (en) * 2020-02-14 2023-04-27 United States Government As Represented By The Department Of Veterans Affairs Novel tdzd analogs as agents that delay, prevent, or reverse age-associated diseases and as anti-cancer and antileukemic agents
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3335147A (en) * 1965-04-29 1967-08-08 Us Vitamin Pharm Corp Anilino-pyridinium-maleimides
US4474598A (en) * 1983-06-27 1984-10-02 Shell Oil Company Oxazolyl-substituted thiadiazolidinediones
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
ES2166328A1 (en) * 2000-05-11 2002-04-01 Consejo Superior Investigacion HETEROCICLIC INHIBITORS OF ENZYME GSK 3 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND HYPERPROLIFERATIVE PROCESSES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3335147A (en) * 1965-04-29 1967-08-08 Us Vitamin Pharm Corp Anilino-pyridinium-maleimides
US4474598A (en) * 1983-06-27 1984-10-02 Shell Oil Company Oxazolyl-substituted thiadiazolidinediones
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
ES2166328A1 (en) * 2000-05-11 2002-04-01 Consejo Superior Investigacion HETEROCICLIC INHIBITORS OF ENZYME GSK 3 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND HYPERPROLIFERATIVE PROCESSES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BISHOP ET AL: "A chemical switch for inhibitor-sensitive alleles of any protein kinase", NATURE, vol. 407, 21 September 2000 (2000-09-21), pages 395 - 401, XP002985907 *
JOHNSON ET AL: "Active and Inactive Protein Kinases: Structural Basis for Regulation", CELL, vol. 85, 19 April 1996 (1996-04-19), pages 149 - 158, XP002985906 *
MARTINEZ ET AL: "First Non-ATP Competitive Glycogen Synthase Kinase 3beta (GSK-3beta) Inhinitors: Thiadiazolidinones (TDZD) as Potential Drugs for the treatment of Alzheimer s Disease", J MED CHEM, vol. 45, 13 February 2002 (2002-02-13), pages 1292 - 1299, XP002292084 *
YUKI ET AL: "Studies on Antiviral Agents. II. Synthesis and biological Activity of Maleimide Derivatives", CHEM PHARM BULL (TOKYO), vol. 15, no. 8, 1967, pages 1101 - 1106, XP002985950 *

Also Published As

Publication number Publication date
WO2005024755A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2005024755A3 (en) Medicaments for the treatment of neurodegenerative disorders or diabetes
WO2003080582A3 (en) Fredericamycin derivatives
EP1511730B8 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2006050389A3 (en) Pyridazine compounds, compositions and methods
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2005063766A3 (en) Bicyclic heterocyclic p-38 kinase inhibitors
WO2001030381A3 (en) Use of csf-1 inhibitors
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2003024965A3 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
WO2006044860A3 (en) Thiadiazole compounds and methods of use
MX2007004882A (en) Xanthine derivatives with hm74a receptor activity.
HRP20130406T1 (en) Medicaments with hm74a receptor activity
ATE454378T1 (en) COMPOUNDS ACTIVE AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
GB0222495D0 (en) Compounds
WO2005046603A3 (en) Pyridine compounds
WO2004071382A3 (en) Substituted heterocycles
GB0121490D0 (en) Ciompounds
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
AU2003260436A1 (en) Pyrimidine compounds
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003283500A1 (en) 1,4-diazabicyclo(3.2.2)nonanecarboxamide derivatives, preparation and therapeutic use thereof related to malfunction of nicotinic receptors
GB0121494D0 (en) Compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase